CN Patent

CN117177752A — 用于治疗mpnst的化合物和组合物

Assigned to Novartis AG · Expires 2023-12-05 · 2y expired

What this patent protects

本发明涉及包含SHP2抑制剂和CDK4/6抑制剂的药物组合；包含该药物组合的药物组合物；以及使用此类组合和组合物在治疗或预防其中SHP2抑制剂与CDK4/6抑制组合是有益的病症中、例如在治疗NF‑1相关的MPNST中的方法。

USPTO Abstract

本发明涉及包含SHP2抑制剂和CDK4/6抑制剂的药物组合；包含该药物组合的药物组合物；以及使用此类组合和组合物在治疗或预防其中SHP2抑制剂与CDK4/6抑制组合是有益的病症中、例如在治疗NF‑1相关的MPNST中的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117177752A
Jurisdiction
CN
Classification
—
Expires
2023-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.